Journal
FUTURE VIROLOGY
Volume 15, Issue 5, Pages 317-323Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fvl-2020-0050
Keywords
ACE2; coronavirus; COVID-19; SARS-CoV-2; zoonotic diseases
Categories
Funding
- Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
- Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Ask authors/readers for more resources
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in several patients who traveled to Wuhan or went to a seafood wholesale market in Wuhan. The phylogenetic tree showed that SARS-CoV-2 was 96.2% identical to bat beta -coronaviruses from lineage B. Also, several studies reported that SARS-CoV-2 uses the SARS-CoV receptor, angiotensin-converting enzyme 2, for entry to target cells. Lung alveolar and small intestine are potential targets for SARS-CoV-2 due to the high expression of the angiotensin-converting enzyme 2 receptor. In this review, we focused on the zoonotic beta -coronaviruses and given there is no specific drug or vaccine for coronavirus disease 2019, we reviewed the literature on the therapy options for SARS and Middle East respiratory syndrome coronavirus infection, in order to discover their possible use in the treatment of SARS-CoV-2 infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available